

CONCISE REVIEW

**OPEN ACCESS**

Full open access to this and thousands of other papers at <http://www.la-press.com>.

## Cinacalcet HCl Treatment in Patients with Chronic Kidney Disease Stage 3–4

Yoshihiro Tominaga

Department of Transplant and Endocrine Surgery, Nagoya Second Red Cross Hospital, Nagoya Japan.  
Email: [ytomi@nagoya2.jrc.or.jp](mailto:ytomi@nagoya2.jrc.or.jp)

---

**Abstract:** It has been clarified in patients with CKD stage 3–4, cinacalcet can reduce PTH levels without severe adverse events, however calcium levels significantly decrease and phosphorus levels increase. Increase of serum phosphorus level by cinacalcet in patients with CKD stage 3–4 is a problematic issue. Undesirable decreases in serum calcium and increases in serum phosphorus caused by cinacalcet require further investigation. For patients with CKD stage 3–4 who suffer from severely advanced 2HPT which cannot be controlled by the usual medical treatment or PTx, cinacalcet can be a useful medication for managing 2HPT.

**Keywords:** cinacalcet, chronic kidney disease, CKD, stage 3–4

---

*Clinical Medicine: Therapeutics* 2009:1 1465–1466

This article is available from <http://www.la-press.com>.

© Libertas Academica Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://www.creativecommons.org/licenses/by/2.0>) which permits unrestricted use, distribution and reproduction provided the original work is properly cited.

The authors grant exclusive rights to all commercial reproduction and distribution to Libertas Academica. Commercial reproduction and distribution rights are reserved by Libertas Academica. No unauthorised commercial use permitted without express consent of Libertas Academica. Contact [tom.hill@la-press.com](mailto:tom.hill@la-press.com) for further information.



Secondary hyperparathyroidism (2HPT) is a common complication in patients with CKD (chronic kidney disease). It has been recommended that patients with CKD stage 3–4, maintain both serum phosphorus and calcium in the normal range to avoid progression of 2HPT and vascular calcification. In patients with CKD 3–4, usual progression of 2HPT can be controlled by dietary phosphate restrictions, phosphate binders, calcium supplementation and vitamin D sterols.

Cinacalcet HCl (cinacalcet) is a new allosteric modulator of the calcium sensing receptor (CaSR), which can reduce PTH secretion by binding to the CaSR in parathyroid cells.<sup>1</sup> Cinacalcet can dramatically reduce PTH levels, serum calcium and phosphorus levels and reduce requirement of PTx in patients with CKD stage 5D.

The use of cinacalcet in CKD stage 3–4 has yet to be approved and remains highly controversial. Only one long-term, randomized, double-blind, placebo controlled study of the efficacy and safety of cinacalcet in patients with CKD stage 3–4 has been published by Chonchol et al.<sup>2</sup> In this study 404 patients with CKD stage 3 or 4 were enrolled. Mean change of i-PTH level was significantly greater in the cinacalcet group than in the placebo group (43.1% vs. 1.1%  $P < 0.001$ ). At week 32, serum calcium levels were 8.9 mg/dl vs. 9.9 mg/dL, and phosphate levels were 4.5 mg/dL vs. 4.0 mg/dL. This study, clarified that in patients with CKD stage 3–4, cinacalcet can reduce PTH levels without a severe adverse event, however calcium levels significantly decreased and phosphorus levels increased. The limitation of this study was the effect of vascular calcification, bone histomorphometry and other clinical outcomes which were not included in the design of this study.

Increase of serum phosphorus levels by cinacalcet in patients with CKD stage 3–4 is a problematic issue. The phenomena can be partly explained by the reduction of tubular re-absorption of phosphorus induced by decreased PTH action and the increase of phosphate absorption from the small intestine due to the additional intake of vitamin D sterols.

Fortunately in this study estimated glomerular filtration rate was not significantly changed by cinacalcet compared with the placebo.

Undesirable decreases in serum calcium and increases in serum phosphorus caused by cinacalcet requires further investigation.

Recently Foluslund et al reported efficacy of cinacalcet for severely advanced 2HPT in patients with CKD stage 3–4 who did not tolerate for PTx.<sup>3</sup> In patients with CKD stage 3–4 who suffer from severely advanced 2HPT which cannot be controlled by usual medical treatment or PTx, cinacalcet can be a useful candidate for managing 2HPT.

## Disclosure

The author reports no conflicts of interest.

## References

1. Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. *Nephrol Dial Transplant*. 2002;17:204–7.
2. Chonchol M, Locatelli F, Abboud HE, et al. A Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. *Am J Kid Dis*. 2009;53:197–207.
3. Forslund T, Koistinen A, Miettinen M. Experience with cinacalcet for secondary hyperparathyroidism in patients with chronic kidney disease stage III and IV. *Clin Med Thera*. 2009;1:801–8.

### Publish with Libertas Academica and every scientist working in your field can read your article

*"I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."*

*"The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I've never had such complete communication with a journal."*

*"LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought."*

#### Your paper will be:

- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

<http://www.la-press.com>